Login to Your Account

Financings Roundup

'Auspex' of Chemistry: $25M for Phase III in Huntington's

By Randy Osborne
Staff Writer

Friday, November 9, 2012
Is it possible, by tweaking the only molecule approved for movement disorders in Huntington's disease, to come up with a new chemical entity that's safer and dosed less often, thanks to a much longer half-life?

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription